➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
McKesson
Harvard Business School
Johnson and Johnson
Boehringer Ingelheim

Last Updated: October 22, 2021

DrugPatentWatch Database Preview

Patent: 7,064,246

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 7,064,246
Title:Use of transposable elements for altering gene expression
Abstract: Methods of repressing expression of a recombinant gene in a cell are provided. The methods include the steps of introducing a transposase DNA binding motif into or adjacent to the gene, and introducing into the cell a transposase that is capable of binding to the transposase DNA binding motif. Methods of producing a population of cells of an organism that vary in their expression of a gene are also provided. The methods involve transfecting the cells with a first polynucleotide sequence encoding the target gene operably linked to a promoter such that the target gene is expressed in the cells, wherein the vector has at least one transposase DNA binding motif within or adjacent to the target gene; and transfecting some of the cells with a second polynucleotide encoding the transposable element operably linked to a second promoter such that the transposable element is expressed in the cells. In these methods, the target gene in the cells transfected with the second polynucleotide exhibits reduced expression when compared to the target gene in the cells that are not transfected with the second polynucleotide. Kits having a first polynucleotide with a gene and a DNA transposase binding motif in or adjacent to the gene, and a second polynucleotide comprising a gene encoding a transposase that is capable of binding to the transposase DNA binding motif are also provided.
Inventor(s): MacRae; Amy F. (St. Louis, MO)
Assignee:
Application Number:10/138,221
Patent Claims:see list of patent claims

Details for Patent 7,064,246

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 1986-06-04 ⤷  Free Forever Trial 2021-05-01
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Free Forever Trial 2021-05-01
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Johnson and Johnson
Colorcon
AstraZeneca
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.